<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04593446</url>
  </required_header>
  <id_info>
    <org_study_id>NCC2020-0138</org_study_id>
    <nct_id>NCT04593446</nct_id>
  </id_info>
  <brief_title>Difference of Surgical Site Infection Between Using Sodium Picosulfate Solution(PicosolutionⓇ) and Oral Sulfate Tablet(ORA·FANGⓇ) in Colorectal Cancer Surgery</brief_title>
  <official_title>Difference of Surgical Site Infection Between Using Sodium Picosulfate Solution(PicosolutionⓇ) and Oral Sulfate Tablet(ORA·FANGⓇ) in Colorectal Cancer Surgery : Phase II. Prospective, Randomised, Multicenter, Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daehang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized study to evaluate the difference in the rate of surgical&#xD;
      site infection between the patients who used Sodium Picosulfate solution(PicosolutionⓇ) and&#xD;
      tablet Oral Sulphate Solution(ORA·FANGⓇ) for bowel preparation before colorectal cancer&#xD;
      surgery .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been reported that tablet oral sulphate solution(ORA·FANGⓇ) showed a successful bowel&#xD;
      cleansing rate of 95.5%, which is similar to compared to sodium picosulfate&#xD;
      solution(PicosolutionⓇ).&#xD;
&#xD;
      In terms of the rate of surgical site infection(SSI), sodium picosulfate&#xD;
      solution(PicosolutionⓇ) showed 8% of SSI rate. However there is no report for the SSI rate of&#xD;
      tablet oral sulphate solution(ORA·FANGⓇ). We aimed to compare the SSI rates between these two&#xD;
      group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of surgical site infection</measure>
    <time_frame>30 days</time_frame>
    <description>The operator will evaluate the rate of the surgical site infection during the postoperative hospitalization period or the first outpatient visit after surgery. We will use the definition of surgical site infection published in 1999 by the Centers for Disease Control and Prevention (CDC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The quality of the bowel preparation</measure>
    <time_frame>during surgery</time_frame>
    <description>The operator will evaluate he quality of the bowel preparation using Arohchick bowel preparation scale during the surgery.&#xD;
Aronchick scale Excellent:5, good:4, fair:3, poor:2, inadequate:1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patient's tolerability for bowel preparation</measure>
    <time_frame>1 day after bowel preparation</time_frame>
    <description>Using questionnaire, the tolerance will be scored after bowel preparation&#xD;
Tolerability score Very comfortable: 5 Comfortable: 4 Fair: 3 Uncomfortable: 2 Very uncomfortable: 1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">414</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Oral Sulfate Tablet(ORA·FANGⓇ)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are randomized into experimental arm will receive 14 pills at 8 pm in the evening 2days before the surgery and another 14 pills on 6am in the morning 1day before the surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Picosulfate Solution(PicosolutionⓇ)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who are randomized into experimental arm will receive 170ml of solution with at 8 pm in the evening 2days before the surgery and another 170ml of solution on 6am in the morning 1day before the surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Sulfate Tablet(ORA·FANGⓇ)</intervention_name>
    <description>Subjects who are randomized into experimental arm will receive 14 pills at 8 pm in the evening 2days before the surgery and another 14 pills on 6am in the morning 1day before the surgery&#xD;
Subjects who are randomized into comparator will receive 170ml of solution with at 8 pm in the evening 2days before the surgery and another 170ml of solution on 6am in the morning 1day before the surgery</description>
    <arm_group_label>Oral Sulfate Tablet(ORA·FANGⓇ)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Picosulfate Solution(PicosolutionⓇ)</intervention_name>
    <description>Sodium Picosulfate Solution(PicosolutionⓇ)</description>
    <arm_group_label>Sodium Picosulfate Solution(PicosolutionⓇ)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who are scheduled for an elective minimally invasive surgery for colorectal&#xD;
             cancer&#xD;
&#xD;
          2. ASA score, 2 or less&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Bowel obstruction&#xD;
&#xD;
          2. FAP or IBD patients&#xD;
&#xD;
          3. Emergency operation&#xD;
&#xD;
          4. Pregnancy&#xD;
&#xD;
          5. Breast feeding&#xD;
&#xD;
          6. Severe medical condition such as severe cardiac,hepatic, or renal failure (creatinine&#xD;
             ≥ 3.0 mg/dL (normal 0.8-1.4 mg/dL)),&#xD;
&#xD;
          7. Allergy to drug and refusal to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyoung-Chul Park, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sung Sil Park, Doctor</last_name>
    <phone>+821092865451</phone>
    <email>51873@ncc.re.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center, Korea</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Sil Park, Doctor</last_name>
      <phone>+821092865451</phone>
      <email>51873@ncc.re.kr</email>
    </contact>
    <contact_backup>
      <last_name>Hyoung-Chul Park, Doctor</last_name>
      <phone>+821027771593</phone>
      <email>greatpa1@ncc.re.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 12, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Sung Sil Park</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>sodium picosulfate solution</keyword>
  <keyword>oral sulfate tablet</keyword>
  <keyword>surgical site infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Picosulfate sodium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

